SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is surging as investors react to the company's recent international expansion into Macau and positive analyst coverage, driving intense speculation about a potential short squeeze. The community is actively debating the significance of upcoming industry conferences and rumors regarding potential government funding, with many traders expressing frustration over coordinated selling pressure while remaining bullish on the firm's long-term pipeline.

FuboTV, Inc. is a consumer-first live TV streaming company with the mission of delivering premium sports, news and entertainment programming that offers greater choice, flexibility and value. The company was founded by David Gandler, Alberto Horihuela Suarez, and Sung Ho Choi on February 20, 2009 and is headquartered in New York, NY.

fuboTV Inc - Ordinary Shares - Class A

fuboTV Inc

FuboTV is facing intense scrutiny and volatility as the company moves toward a reverse stock split, fueling deep divisions among retail investors. While some holders are speculating on a potential institutional rebound or a short squeeze, many are venting frustration over the lack of positive guidance and are actively positioning themselves to short the stock in anticipation of further downside.

AleAnna, Inc. operates as a technology-driven energy company, which engages in supplying low-carbon natural gas and renewable natural gas to Italy. The company was founded in 2007 and is headquartered in Dallas, TX.

AleAnna Inc. - Ordinary Shares - Class A

AleAnna Inc. is surging as investors capitalize on a growing natural gas supply crisis triggered by conflict in the Middle East and damage to critical energy infrastructure. Community sentiment remains highly bullish, with active discussions focusing on the stock's potential for a short squeeze, its role as a strategic European LNG supplier, and heavy retail accumulation as volume levels continue to climb.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is facing intense downward pressure and negative sentiment, with the community actively debating whether the stock's significant pullback represents a generational buying opportunity or a deeper structural decline. Investors are polarized over the company's heavy AI spending and the ongoing volatility, with many expressing frustration over the stock's persistent underperformance compared to the broader tech sector.

Fundrise Innovation Fund LLC. - Common Shares of Limited Liability Company Interests

Fundrise Innovation Fund 

The Fundrise Innovation Fund (VCX) is seeing intense volatility and record-high trading volume as retail investors react to its direct exposure to high-profile private AI firms like OpenAI, Anthropic, and SpaceX. While bullish sentiment is driven by the fund's unique access to these sought-after holdings, many market participants are actively debating the sustainability of its current market price compared to its intrinsic net asset value, frequently comparing the situation to previous low-float 'pump and dump' market events.

Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A, Silver, Giulio Draetta, Michael G. Kauffman, and Sharon Shacham on December 22, 2008, and is headquartered in Newton, MA.

Karyopharm Therapeutics Inc

Karyopharm Therapeutics is trending as investors digest mixed results from its Phase 3 SENTRY trial in myelofibrosis, which met spleen volume reduction goals but missed on key symptom endpoints. Community discourse is highly polarized, with some highlighting the strong overall survival signal as a potential path for future regulatory success, while others express deep frustration over the company's financial runway and recent private placement deals.

Venture Global, Inc. engages in the provision of United States liquefied natural gas sourced from resource rich North American natural gas basins. It operates through the following segments: Calcasieu Project, Plaquemines Project, CP2 Project, and Sales and shipping. The company was founded by Michael Sabel and Robert Pender in 2023 and is headquartered in Arlington, VA.

Venture Global Inc. - Ordinary Shares - Class A

Venture Global Inc

Venture Global is surging as heightened geopolitical tensions in the Middle East and physical damage to major LNG infrastructure in Qatar trigger fears of a severe, long-term global supply shortage. Investors are closely watching the stock for a potential squeeze, with the community highlighting the company's strategic position to capture market share and benefit from elevated spot prices amid ongoing industry disruption.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BCRX is currently surging on high volume driven by unconfirmed market rumors of potential M&A activity, fueling long-standing community speculation about a possible buyout. Investors are actively debating the credibility of these reports while highlighting the company's strong revenue growth and significant short interest as key factors that could intensify volatility.

Figma, Inc. is an AI-powered design platform that enables seamless collaboration across the entire product development lifecycle. Its products include FigJam, Figma Slides, Figma Design, Figma Draw, Dev Mode, Figma Sites, Figma Buzz and Figma Make. The company was founded by Dylan Joseph Field and Evan Darrow Wallace in 2012 and is headquartered in San Francisco, CA.

Figma Inc. - Ordinary Shares - Class A

Figma

Figma is experiencing significant volatility driven by heavy institutional buying, including major insider purchases and increased interest from funds like ARK Invest, even as short sellers attempt to suppress the price. The community is actively debating the stock's long-term potential in an AI-dominated workflow, with many investors focusing on the company's strong earnings beat, projected 40% revenue growth, and the shift toward monetizing AI credits as catalysts for an upward move.

Far below the surface, where light no longer reaches and noise collapses into silence, the Sperm Whale endures.  It does not rely on speed or spectacle. It survives through mass, intelligence, and absolute awareness of its surroundings.  This project is shaped by the same principle — strength formed under pressure, movement guided by understanding, and conviction built where others cannot remain.  While the surface reacts, the deep decides.

The Sperm Whale

SPERMWHALE is trending as a highly speculative, low-cap meme coin that has polarized the community, with some traders touting its potential for explosive gains while others warn it is a classic pump-and-dump scheme. Discussion centers on its rapid price volatility, accessibility via DEX platforms, and ongoing debate over whether its current price action reflects genuine accumulation or manipulative tactics by top holders.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

TrueBlue Named One of the 2026 Worlds Most Ethical Companies, Reinforcing Commitment to Ethical Leadership and Strong Governance

TrueBlue (NYSE: TBI), a leading provider of specialized workforce solutions, today announced it has been recognized as one of the Worlds Most Ethical Companies by Ethisphere, a global leader in...

TrueBlue Responds to Misleading Statements From EHS Investments

TrueBlue, Inc. (NYSE: TBI) (TrueBlue or the Company) today issued the following statement in response to the recent statements made by EHS Investments (EHS): On February 18, 2026, TrueBlue reported...

EHS Comments on Disappointing TrueBlue Fourth Quarter Earnings Results

EHS Comments on Disappointing TrueBlue Fourth Quarter Earnings Results EHS Comments on Disappointing TrueBlue Fourth Quarter Earnings Results PR Newswire NEW YORK, March 3, 2026 Argues Continued...

TrueBlue (NYSE:TBI) CEO Taryn Owen Buys 20,400 Shares

TrueBlue, Inc. (NYSE:TBI - Get Free Report) CEO Taryn Owen bought 20,400 shares of the company's stock in a transaction on Tuesday, February 24th. The shares were bought at an average price of $3.79...

Insider Buying: TrueBlue (NYSE:TBI) CEO Purchases 20,400 Shares of Stock

TrueBlue, Inc. (NYSE:TBI - Get Free Report) CEO Taryn Owen purchased 20,400 shares of the stock in a transaction on Tuesday, February 24th. The shares were acquired at an average cost of $3.79 per...

TrueBlue Appoints Mike Kruszewski to President of PeopleReady On-Demand

TrueBlue (NYSE: TBI), a leading provider of specialized workforce solutions, today announced that Mike Kruszewski has been appointed President of PeopleReady On-Demand. In his expanded role, Mr...

TrueBlue to Participate in Truist Securities Inaugural Human Capital Virtual Conference

TrueBlue (NYSE: TBI), a leading provider of specialized workforce solutions, today announced that it will participate in Truist Securities inaugural Human Capital Virtual Conference on Thursday...

Carl Schweihs Purchases 12,500 Shares of TrueBlue (NYSE:TBI) Stock

TrueBlue, Inc. (NYSE:TBI - Get Free Report) CFO Carl Schweihs acquired 12,500 shares of the stock in a transaction on Monday, February 23rd. The stock was purchased at an average cost of $3.72 per...

TrueBlue (NYSE:TBI) CFO Carl Schweihs Buys 12,500 Shares

TrueBlue, Inc. (NYSE:TBI - Get Free Report) CFO Carl Schweihs bought 12,500 shares of the firm's stock in a transaction dated Monday, February 23rd. The stock was acquired at an average cost of $3.72...

Equities Analysts Issue Forecasts for TrueBlue Q1 Earnings

TrueBlue, Inc. (NYSE:TBI - Free Report) - Equities researchers at Sidoti cut their Q1 2026 EPS estimates for shares of TrueBlue in a report released on Thursday, February 19th. Sidoti analyst M...

TrueBlue, Inc. engages in the provision of staffing, recruitment process outsourcing and managed service provider solutions. It operates through the following segments: PeopleReady, PeopleManagement, and PeopleScout. The PeopleReady segment offers staffing solutions for blue-collar, contingent on-demand and skilled labor to a broad range of industries that include retail, manufacturing, warehousing, logistics, energy, construction, hospitality and others. The PeopleManagement segment supplies contingent labor and outsourced industrial workforce solutions. The PeopleScout segment covers the provision of permanent employee recruitment process outsourcing for its customers for all major industries and jobs. The company was founded by John Ross Coghlan and Glenn Welstad in 1989 and is headquartered in Tacoma, WA.

Current Price	$3.62
Prev Close	$3.63
Open	$3.60
Dividend Yield	0.00%
50-Day Moving Average	$4.52
Beta	0.85
Avg. Volume	289,958.04
PE Ratio	-2.26

52-Week High	$7.78
52-Week Low	$3.42
Market Capitalization	$109.13M
EPS (Annual)	-$1.61
Price to Book	0.40
Revenue Per Employee	$461,713.43

TBI
TrueBlue Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest TBI News

TBITrueBlue Inc